

# Influenza A(H3N2) cell culture-derived<sup>1</sup> candidate vaccine viruses, candidate recombinant vaccine antigen(s), and candidate nucleic acid-based vaccine construct(s) for the development and production of vaccines for use in the 2026 southern hemisphere influenza season

Human influenza virus isolation using a certified cell line (e.g. MDCK 33016 PF<sup>a</sup>, NIID-MDCK<sup>b</sup>) has been performed by WHO Collaborating Centres (CCs) of the WHO Global Influenza Surveillance and Response System (GISRS). The WHO CCs also perform antigenic and genetic analysis on the cell cultured Candidate Vaccine Viruses (ccCVVs). Unless otherwise specified, these ccCVVs have passed two-way haemagglutination inhibition (HI) or virus neutralization (VN) tests against the cell culture propagated prototype viruses matching the WHO recommendation<sup>2</sup>. **No other testing (including adventitious agents) has been performed** on these ccCVVs by the WHO CCs. National or regional control authorities generally approve the manufacture, composition and formulation of influenza vaccines used in each country<sup>3</sup>. Manufacturers should consult relevant national or regional control authorities regarding the suitability of using these ccCVVs for influenza vaccine production.

<sup>a</sup> Derived from MDCK cell line approved for use for human vaccine manufacture in compliance with Ph. Eur. general chapter 5.2.3 by Novartis/Seqirus

<sup>b</sup> Derived from MDCK cell line developed by the National Institute of Infectious Diseases (NIID), Japan

**26 September 2025 (Last updated 02 February 2026)**

**Cell culture-based candidate vaccine viruses (ccCVVs) antigenically like A/Sydney/1359/2024 (MDCK SIAT cell-derived) - Accession number (GISaid): EPI\_ISL\_19711425**

ccCVV	Candidate Vaccine Virus	Type of virus or reassortant	Certified cell line used for isolation and propagation	Developing institute	Passage level available	Available from
A/Singapore/GP20238/2024	Wild type virus		MDCK 33016 PF	VIDRL, Australia	P2	VIDRL, Australia
A/Sydney/68/2025*						
A/Victoria/317/2025*						

\*Two-way antigenic testing pending

**For recombinant protein- or nucleic acid-based vaccines, it is recommended that the protein sequence(s) closely matches the sequence of A/Sydney/1359/2024 (MDCK SIAT cell-derived).**

**Institutes contact details for candidate vaccine viruses orders/information:**

VIDRL: [enquiries@influenzacentre.org](mailto:enquiries@influenzacentre.org)

<sup>1</sup> For egg-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses/>

<sup>2</sup> <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations>

<sup>3</sup> <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

## Reference antigens (freeze-dried)

Parent virus	Starting materials		Ref Ag Lot number	Unitage ( $\mu$ g HA/ml)	Available from
	Candidate vaccine virus	egg or cell			
A/Singapore/GP20238/2024	IVR-227	Egg	2025/158B*	112	TGA, Australia

\*New reagents shown in blue

## Sheep Antisera

Purified HA from		Order Lot number	Available from
Parent virus	Egg or cell		
A/Singapore/GP20238/2024-like	Egg	AS466*	TGA, Australia

\*New reagents shown in blue

**WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:**

**MHRA:** [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

**TGA:** [influenza.reagents@tga.gov.au](mailto:influenza.reagents@tga.gov.au)

For reagents available from **CBER**, email [CBERShippingRequests@fda.hhs.gov](mailto:CBERShippingRequests@fda.hhs.gov).

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>).

For general enquiries, please contact [gisrs-whohq@who.int](mailto:gisrs-whohq@who.int)